Browse > Article
http://dx.doi.org/10.4014/jmb.1109.09013

In Vitro Activities of Antimicrobials Against Brucella abortus Isolates from Cattle in Korea During 1998-2006  

Heo, Eun-Jeong (Animal, Plant and Fisheries Quarantine and Inspection Agency)
Kang, Sung-Il (Animal, Plant and Fisheries Quarantine and Inspection Agency)
Kim, Jong-Wan (Animal, Plant and Fisheries Quarantine and Inspection Agency)
Her, Moon (Animal, Plant and Fisheries Quarantine and Inspection Agency)
Cho, Dong-Hee (Animal, Plant and Fisheries Quarantine and Inspection Agency)
Cho, Yun-Sang (Animal, Plant and Fisheries Quarantine and Inspection Agency)
Hwang, In-Yeong (Animal, Plant and Fisheries Quarantine and Inspection Agency)
Moon, Jin-San (Animal, Plant and Fisheries Quarantine and Inspection Agency)
Wee, Sung-Hwan (Animal, Plant and Fisheries Quarantine and Inspection Agency)
Jung, Suk-Chan (Animal, Plant and Fisheries Quarantine and Inspection Agency)
Nam, Hyang-Mi (Animal, Plant and Fisheries Quarantine and Inspection Agency)
Publication Information
Journal of Microbiology and Biotechnology / v.22, no.4, 2012 , pp. 567-570 More about this Journal
Abstract
In vitro activities of 13 antibiotics were assessed against 85 Brucella abortus isolates from naturally infected cattle in the Republic of Korea during 1998-2006, using broth microdilution test. Tetracyclines showed the most excellent activity against B. abortus, displaying MIC values of 0.5 ${\mu}g/ml$ or below. In particular, minocycline showed the lowest $MIC_{50/90}$ values (0.125/0.125 ${\mu}g/ml$) in this study. Among four fluoroquinolones tested, ciprofloxacin ($MIC_{50/90}$, 0.5/1 ${\mu}g/ml$) and norfloxacin ($MIC_{50/90}$, 8/8 ${\mu}g/ml$) had the most and the least activities, respectively. Gentamicin ($MIC_{50/90}$, 1/1 ${\mu}g/ml$) was more effective than streptomycin, erythromycin, rifampin, and chloramphenicol ($MIC_{50/90}$, 2/2 ${\mu}g/ml$).
Keywords
Antimicrobial susceptibility; Brucella abortus; cattle;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
연도 인용수 순위
  • Reference
1 Al-Tawfiq, J. 2008. Therapeutic options for human brucellosis. Expert Rev. Anti. Infect. Ther. 6: 109-120.   DOI   ScienceOn
2 Al Dahouk, S., R. Hagen, K. Nockler, H. Tomaso, M. Wittig, H. Scholz, et al. 2005. Failure of a short-term antibiotic therapy for human brucellosis using ciprofloxacin. Chemotherapy 51: 352-356.   DOI   ScienceOn
3 Solera, J., A. Espinosa, E. Martinez-Alfaro, L. Sanchez, P. Geijo, E. Navarro, et al. 1997. Treatment of human brucellosis with doxycycline and gentamicin. Antimicrob. Agents Chemother. 41: 80-84.
4 Wee, S. H., H. M. Nam, and C. H. Kim. 2008. Emergence of brucellosis in cattle in the Republic of Korea. Vet. Rec. 162: 556-557.   DOI   ScienceOn
5 WHO. 1986: Joint FAO/WHO Expert Committee on Brucellosis: Sixth report. World Health Organization.
6 Bodur, H., N. Balaban, S. Aksaray, V. Yetener, E. Akinci, A. Colpan, and A. Erbay. 2003. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand. J. Infect. Dis. 35: 337-338.   DOI   ScienceOn
7 Almuneef, M., Z. Memish, M. Al-Shaalan, E. Al-Banyan, S. Al-Alola, and H. Balkh. 2003. Brucella melitensis bacteremia in children: Review of 62 cases. J. Chemother. 15: 76-80.   DOI
8 Ariza, J., M. Bosilkovski, A. Cascio, J. D. Colmenero, M. J. Corbel, M. E. Falagas, et al. 2007. Perspectives for the treatment of brucellosis in the 21st century: The Ioannina recommendations. PLoS Med. 4: 1872-1878
9 Baykam, N., H. Esener, O. Ergonul, S. Eren, A. K. Celikbas, and B. Dokuzo guz. 2004. In vitro antimicrobial susceptibility of Brucella species. Int. J. Antimicrob. Agents 23: 405-407.   DOI   ScienceOn
10 Boschiroli, M., V. Foulongne, and D. O'Callaghan. 2001. Brucellosis: A worldwide zoonosis. Curr. Opin. Microbiol. 4: 58-64.   DOI   ScienceOn
11 Bricker, B. and S. Halling. 1995. Enhancement of the Brucella AMOS PCR assay for differentiation of Brucella abortus vaccine strains S19 and RB51. J. Clin. Microbiol. 33: 1640-1642.
12 CLSI. 2010. Performance standards for antimicrobial susceptibility testing. M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA, USA.
13 Dorsch, M., E. Moreno, and E. Stackebrandt. 1989. Nucleotide sequence of the 16S rRNA from Brucella abortus. Nucleic. Acids. Res. 17: 1765.   DOI   ScienceOn
14 Ewalt, D. and B. Bricker. 2000. Validation of the abbreviated Brucella AMOS PCR as a rapid screening method for differentiation of Brucella abortus field strain isolates and the vaccine strains, 19 and RB51. J. Clin. Microbiol. 38: 3085-3086.
15 Hall, W. 1990. Modern chemotherapy for brucellosis in humans. Rev. Infect. Dis. 12: 1060-1099.   DOI
16 Garcia-Rodriguez, J., J. Garcia Sanchez, and I. Trujillano. 1991. Lack of effective bactericidal activity of new quinolones against brucella spp. Antimicrob. Agents chemother. 35: 756-759.   DOI   ScienceOn
17 Gargani, G. and A. Pacetti. 1986. Sensitivity of 115 strains of the genus Brucella to some antibiotics (cephalosporins, ureidopenicillins and aminoglycosides). Chemioterapia. 5: 7-13.
18 Hall, W. and R. Manion. 1970. In vitro susceptibility of Brucella to various antibiotics. Appl. Environ. Microb. 20: 600-604.
19 Kim, S. G., Y. H. Kim, M. H. Cho, Y. J. Lee, and C. K. Park. 2009. Biochemical characteristics of Brucella abortus isolated from cattle in Gyungbuk Province. Korean J. Vet. Serv. 32: 139-146.
20 Lopez-Merino, A., A. Contreras-Rodriguez, R. Migranas-Ortiz, R. Orrantia-Gradin, G. Hernandez-Oliva, A. Gutierrez-Rubio, and O. Cardenosa. 2004. Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand. J. Infect. Dis. 36: 636-638.   DOI   ScienceOn
21 Mantur, B. G., S. K. Amamath, and R. S. Shinde. 2007. Review of clinical and laboratory features of human brucellosis. Indian J. Med. Microbiol. 25: 188-202.   DOI   ScienceOn
22 Marianelli, C., C. Graziani, C. Santagelo, M. T. Xibilia, A. Imbriani, A. Amato, et al. 2007. Molecular epidemiological and antibiotic susceptibility characterization of Brucella isolates from humans in Sicily, Italy. J. Clin. Microbiol. 45: 2923-2928.   DOI   ScienceOn
23 Nielsen, K. and J. R. Duncan. 1990. Animal brucellosis. 1st Ed. CRC press.
24 Marianelli, C., F. Ciuchini, M. Tarantino, P. Pasquali, and R. Adone. 2004. Genetic bases of the rifampin resistance phenotype in Brucella spp. J. Clin. Microbiol. 42: 5439-5443.   DOI   ScienceOn
25 Maves, R. C., R. Castillo, A. Guillen, B. Espinosa, R. Meza, N. Espinoza, et al. 2011. Antimicrobial susceptibility of Brucella melitensis isolates in Peru. Antimicrob. Agents Chemother. 55: 1279-1281.   DOI   ScienceOn
26 Mortensen, J., D. Moore, J. Clarridge, and E. Young. 1986. Antimicrobial susceptibility of clinical isolates of Brucella. Diagn. Micro. Infect. Dis. 5: 163-169.   DOI   ScienceOn
27 Park, M. S., Y. S. Woo, M. J. Lee, S. K. Shim, H. K. Lee, Y. S. Choi, et al. 2003. The First Case of Human Brucellosis in Korea. Infect. Chemother. 35: 461-466.
28 Park, M. Y., C. S. Lee, Y. S. Choi, S. J. Park, J. S. Lee, and H. B. Lee. 2005. A sporadic outbreak of human brucellosis in Korea. J. Korean Med. Sci. 20: 941-946.   DOI   ScienceOn
29 Rolain, J., M. Maurin, and D. Raoult. 2000. Bactericidal effect of antibiotics on Bartonella and Brucella spp.: Clinical implications. J. Antimicrob. Chemoth. 46: 811-814.   DOI   ScienceOn
30 Romero, C., C. Gamazo, M. Pardo, and I. Lopez-Goni. 1995. Specific detection of Brucella DNA by PCR. J. Clin. Microbiol. 33: 615-617.
31 Shaalan, M., Z. Memish, S. Mahmoud, A. Alomari, M. Khan, M. Almuneef, and S. Alalola. 2002. Brucellosis in children: clinical observations in 115 cases. Int. J. Infect. Dis. 6: 182-186.   DOI   ScienceOn